Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Phase 1 Terminated
11 enrolled
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Phase 1/2 Terminated
93 enrolled 27 charts
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2 Terminated
31 enrolled 18 charts
GLEAN-1
Phase 1 Terminated
34 enrolled
FIRCE-1
Phase 2 Terminated
101 enrolled
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
Phase 1 Terminated
10 enrolled
Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL
Phase 1/2 Terminated
13 enrolled 10 charts
C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma
Phase 1 Terminated
2 enrolled
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Phase 2 Terminated
55 enrolled
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
Phase 1/2 Terminated
9 enrolled 11 charts
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 Terminated
3 enrolled 11 charts
CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies
Phase 1 Terminated
4 enrolled
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
Phase 1/2 Terminated
8 enrolled
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
Phase 1 Terminated
55 enrolled
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Phase 1 Terminated
21 enrolled
Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
Phase 1 Terminated
27 enrolled
FT516 in Subjects With Advanced Hematologic Malignancies
Phase 1 Terminated
72 enrolled
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Phase 1 Terminated
98 enrolled
PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)
Phase 2 Terminated
5 enrolled 6 charts
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Phase 1/2 Terminated
51 enrolled 18 charts
Safety Study of SEA-CD40 in Cancer Patients
Phase 1 Terminated
159 enrolled
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase 1 Terminated
41 enrolled
Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers
Phase 1 Terminated
5 enrolled
Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
Phase 1/2 Terminated
19 enrolled 15 charts
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
Phase 1 Terminated
18 enrolled
MT-3724NHL001
Phase 1/2 Terminated
38 enrolled 20 charts
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
Phase 1 Terminated
10 enrolled
T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma
Phase 1 Terminated
2 enrolled 14 charts
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
Terminated
22 enrolled
Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma
Phase 1 Terminated
4 enrolled
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
Phase 2 Terminated
20 enrolled 15 charts
Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma
Terminated
1 enrolled
SIGNATURE
Phase 2 Terminated
47 enrolled 13 charts
Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma
Phase 1 Terminated
120 enrolled
Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL
Phase 1/2 Terminated
5 enrolled 12 charts
Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
Phase 1/2 Terminated
29 enrolled 16 charts
Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase 1 Terminated
16 enrolled 10 charts
A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients
Phase 1 Terminated
1 enrolled
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Phase 2 Terminated
4 enrolled 13 charts
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
Phase 2 Terminated
81 enrolled 15 charts
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Phase 2 Terminated
24 enrolled 10 charts
Study of ET190L1 ARTEMISâ„¢ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma
Phase 1 Terminated
4 enrolled
Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma
Phase 2 Terminated
1 enrolled 5 charts
DRBEAT
Phase 2 Terminated
11 enrolled 10 charts
BIBLOS
Phase 1 Terminated
85 enrolled
VRCD
Phase 2 Terminated
12 enrolled 7 charts
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Phase 2 Terminated
87 enrolled 18 charts
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Phase 2 Terminated
14 enrolled 11 charts
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
Phase 2 Terminated
3 enrolled 13 charts
Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma
Phase 2 Terminated
75 enrolled